In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against Acinetobacter baumannii Strains Recovered from Clinical Samples

Background: Cefiderocol is a siderophore cephalosporin that exhibits antimicrobial activity against most multi-drug resistant Gram-negative bacteria, including Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas malto...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Davide Carcione, Claudia Siracusa, Adela Sulejmani, Roberta Migliavacca, Alessandra Mercato, Aurora Piazza, Luigi Principe, Nicola Clementi, Nicasio Mancini, Valerio Leoni, Jari Intra
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	antimicrobial resistance nosocomial infection cefiderocol siderophore-cephalosporin <i>Acinetobacter baumannii</i> Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/da982e6f724b42c58e58628aa31e36b7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:da982e6f724b42c58e58628aa31e36b7
record_format	dspace
spelling	oai:doaj.org-article:da982e6f724b42c58e58628aa31e36b72021-11-25T16:22:33ZIn Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against <i>Acinetobacter baumannii</i> Strains Recovered from Clinical Samples10.3390/antibiotics101113092079-6382https://doaj.org/article/da982e6f724b42c58e58628aa31e36b72021-10-01T00:00:00Zhttps://www.mdpi.com/2079-6382/10/11/1309https://doaj.org/toc/2079-6382Background: Cefiderocol is a siderophore cephalosporin that exhibits antimicrobial activity against most multi-drug resistant Gram-negative bacteria, including Enterobacterales, <i>Pseudomonas aeruginosa</i>, <i>Acinetobacter baumannii</i>, and <i>Stenotrophomonas maltophilia</i>. Methods: A total of 20 multidrug-resistant <i>A. baumannii</i> strains were isolated from 2020 to 2021, molecularly characterized and tested to assess the in vitro antibacterial activity of cefiderocol. Thirteen strains were carbapenem-hydrolysing oxacillinase OXA-23-like producers, while seven were non-OXA-23-like producers. Minimum inhibitory concentrations (MICs) were determined by broth microdilution, considered as the gold standard method. Disk diffusion test was also carried out using iron-depleted CAMHB plates for cefiderocol. Results: Cefiderocol MICs ranged from 0.5 to 1 mg/L for OXA-23-like non-producing <i>A. baumannii</i> strains and from 0.25 to >32 mg/L for OXA-23-like producers, using the broth microdilution method. Cefiderocol MIC<sub>90</sub> was 8 mg/L. Diameter of inhibition zone of cefiderocol ranged from 18 to 25 mm for OXA-23-like non-producers and from 15 to 36 mm for OXA-23-like producers, using the diffusion disk method. A large variability and a low reproducibility were observed during the determination of diameter inhibition zone. Molecular characterization showed that all isolates presented the ISAba1 genetic element upstream the <i>bla</i>OXA-51. Among OXA-23-like non-producers, four were <i>bla</i>OXA-58 positive and two were negative for all the resistance determinants analyzed. Conclusions: Cefiderocol showed in vitro antimicrobial activity against both carbapenem-susceptible and non-susceptible <i>A. baumannii</i> strains, although some OXA-23-like producers were resistant. Further clinical studies are needed to consolidate the role of cefiderocol as an antibiotic against MDR <i>A. baumannii</i>.Davide CarcioneClaudia SiracusaAdela SulejmaniRoberta MigliavaccaAlessandra MercatoAurora PiazzaLuigi PrincipeNicola ClementiNicasio ManciniValerio LeoniJari IntraMDPI AGarticleantimicrobial resistancenosocomial infectioncefiderocolsiderophore-cephalosporin<i>Acinetobacter baumannii</i>Therapeutics. PharmacologyRM1-950ENAntibiotics, Vol 10, Iss 1309, p 1309 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antimicrobial resistance nosocomial infection cefiderocol siderophore-cephalosporin <i>Acinetobacter baumannii</i> Therapeutics. Pharmacology RM1-950
spellingShingle	antimicrobial resistance nosocomial infection cefiderocol siderophore-cephalosporin <i>Acinetobacter baumannii</i> Therapeutics. Pharmacology RM1-950 Davide Carcione Claudia Siracusa Adela Sulejmani Roberta Migliavacca Alessandra Mercato Aurora Piazza Luigi Principe Nicola Clementi Nicasio Mancini Valerio Leoni Jari Intra In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against <i>Acinetobacter baumannii</i> Strains Recovered from Clinical Samples
description	Background: Cefiderocol is a siderophore cephalosporin that exhibits antimicrobial activity against most multi-drug resistant Gram-negative bacteria, including Enterobacterales, <i>Pseudomonas aeruginosa</i>, <i>Acinetobacter baumannii</i>, and <i>Stenotrophomonas maltophilia</i>. Methods: A total of 20 multidrug-resistant <i>A. baumannii</i> strains were isolated from 2020 to 2021, molecularly characterized and tested to assess the in vitro antibacterial activity of cefiderocol. Thirteen strains were carbapenem-hydrolysing oxacillinase OXA-23-like producers, while seven were non-OXA-23-like producers. Minimum inhibitory concentrations (MICs) were determined by broth microdilution, considered as the gold standard method. Disk diffusion test was also carried out using iron-depleted CAMHB plates for cefiderocol. Results: Cefiderocol MICs ranged from 0.5 to 1 mg/L for OXA-23-like non-producing <i>A. baumannii</i> strains and from 0.25 to >32 mg/L for OXA-23-like producers, using the broth microdilution method. Cefiderocol MIC<sub>90</sub> was 8 mg/L. Diameter of inhibition zone of cefiderocol ranged from 18 to 25 mm for OXA-23-like non-producers and from 15 to 36 mm for OXA-23-like producers, using the diffusion disk method. A large variability and a low reproducibility were observed during the determination of diameter inhibition zone. Molecular characterization showed that all isolates presented the ISAba1 genetic element upstream the <i>bla</i>OXA-51. Among OXA-23-like non-producers, four were <i>bla</i>OXA-58 positive and two were negative for all the resistance determinants analyzed. Conclusions: Cefiderocol showed in vitro antimicrobial activity against both carbapenem-susceptible and non-susceptible <i>A. baumannii</i> strains, although some OXA-23-like producers were resistant. Further clinical studies are needed to consolidate the role of cefiderocol as an antibiotic against MDR <i>A. baumannii</i>.
format	article
author	Davide Carcione Claudia Siracusa Adela Sulejmani Roberta Migliavacca Alessandra Mercato Aurora Piazza Luigi Principe Nicola Clementi Nicasio Mancini Valerio Leoni Jari Intra
author_facet	Davide Carcione Claudia Siracusa Adela Sulejmani Roberta Migliavacca Alessandra Mercato Aurora Piazza Luigi Principe Nicola Clementi Nicasio Mancini Valerio Leoni Jari Intra
author_sort	Davide Carcione
title	In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against <i>Acinetobacter baumannii</i> Strains Recovered from Clinical Samples
title_short	In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against <i>Acinetobacter baumannii</i> Strains Recovered from Clinical Samples
title_full	In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against <i>Acinetobacter baumannii</i> Strains Recovered from Clinical Samples
title_fullStr	In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against <i>Acinetobacter baumannii</i> Strains Recovered from Clinical Samples
title_full_unstemmed	In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against <i>Acinetobacter baumannii</i> Strains Recovered from Clinical Samples
title_sort	in vitro antimicrobial activity of the siderophore cephalosporin cefiderocol against <i>acinetobacter baumannii</i> strains recovered from clinical samples
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/da982e6f724b42c58e58628aa31e36b7
work_keys_str_mv	AT davidecarcione invitroantimicrobialactivityofthesiderophorecephalosporincefiderocolagainstiacinetobacterbaumanniiistrainsrecoveredfromclinicalsamples AT claudiasiracusa invitroantimicrobialactivityofthesiderophorecephalosporincefiderocolagainstiacinetobacterbaumanniiistrainsrecoveredfromclinicalsamples AT adelasulejmani invitroantimicrobialactivityofthesiderophorecephalosporincefiderocolagainstiacinetobacterbaumanniiistrainsrecoveredfromclinicalsamples AT robertamigliavacca invitroantimicrobialactivityofthesiderophorecephalosporincefiderocolagainstiacinetobacterbaumanniiistrainsrecoveredfromclinicalsamples AT alessandramercato invitroantimicrobialactivityofthesiderophorecephalosporincefiderocolagainstiacinetobacterbaumanniiistrainsrecoveredfromclinicalsamples AT aurorapiazza invitroantimicrobialactivityofthesiderophorecephalosporincefiderocolagainstiacinetobacterbaumanniiistrainsrecoveredfromclinicalsamples AT luigiprincipe invitroantimicrobialactivityofthesiderophorecephalosporincefiderocolagainstiacinetobacterbaumanniiistrainsrecoveredfromclinicalsamples AT nicolaclementi invitroantimicrobialactivityofthesiderophorecephalosporincefiderocolagainstiacinetobacterbaumanniiistrainsrecoveredfromclinicalsamples AT nicasiomancini invitroantimicrobialactivityofthesiderophorecephalosporincefiderocolagainstiacinetobacterbaumanniiistrainsrecoveredfromclinicalsamples AT valerioleoni invitroantimicrobialactivityofthesiderophorecephalosporincefiderocolagainstiacinetobacterbaumanniiistrainsrecoveredfromclinicalsamples AT jariintra invitroantimicrobialactivityofthesiderophorecephalosporincefiderocolagainstiacinetobacterbaumanniiistrainsrecoveredfromclinicalsamples
_version_	1718413230269792256

In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against <i>Acinetobacter baumannii</i> Strains Recovered from Clinical Samples

Ejemplares similares